Deanna Kornacki

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib et al. · Journal of Hematology & Oncology · 2017 · 427 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo

David Rosmarin, Thierry Passeron, Amit G. Pandya et al. · New England Journal of Medicine · 2022 · 266 citations

Medicine, Dermatology, Pharmacology +15

Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study

Elise A. Olsen, Deanna Kornacki, Kang Sun et al. · Journal of the American Academy of Dermatology · 2019 · 63 citations

Medicine, Dermatology, Pharmacotherapy +7

A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)

Nehal J. Lakhani, Rasha Cosman, Udai Banerji et al. · ESMO Open · 2024 · 23 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 – 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study

Moshe Talpaz, Josef T. Prchal, Lawrence B. Afrin et al. · Clinical Lymphoma Myeloma & Leukemia · 2021 · 17 citations · Full text

Medicine, Hematology, Pharmacology +13